[ACCESSWIRE]
NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cellceutix Corp. (OTC: CTIX), Agrieuro Corp. (OTC: EURI), Cannabis Science Inc. (OTC: CBIS) and Hyperdynamics Corporation (OTC: HDYN). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
To access our full PDF reports for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
CTIX Research Report: http://www.traders-choice.com/pdf?s=CTIX
EURI Research Report: http://www.traders-choice.com/pdf?s=EURI
CBIS Research Report: http://www.traders-choice.com/pdf?s=CBIS
HDYN Research Report: http://www.traders-choice.com/pdf?s=HDYN
============
Highlights from today's reports include:
On Friday, October 30, 2015, the NASDAQ Composite ended at 5,053.75, down 0.40%, the Dow Jones Industrial Average edged 0.52% lower, to finish the day at 17,663.54, and the S&P 500 closed at 2,079.36, down 0.48%.
- Cellceutix Corp.'s stock edged higher by 6.85% to close Friday's session at USD 1.56. The company's shares oscillated between USD 1.47 and USD 1.66, during the session. The stock recorded a trading volume of 0.55 million shares, which was above its 50-day daily average volume of 0.26 million shares and above its 52-week average volume of 0.40 million shares. Over the last three days, Cellceutix Corp.'s shares have advanced 16.85% and in the past one week it has moved up 41.18%. However, over the last three months, the stock has lost 39.30%. In the past six months also, the shares have shed 46.39%. Meanwhile, the stock is trading at a price to book ratio of 24.48. The historical PB ratio is near to 43.26. Moreover, the market cap is USD 184.3 million. Cellceutix Corp., the clinical-stage pharmaceutical company, is focused on developing and/or acquiring small molecule therapies. The Company's clinical programs include Kevetrin, Prurisol, Brilacidin and Brilacidin-OM.
- The stock of Agrieuro Corp. gained 95.24% to close the trading session at USD 0.41, above its 50-day moving average of USD 0.09. The shares moved in the range of USD 0.23 and USD 0.44 while recording a trading volume of 2.75 million shares, which was greater than its 150-day daily average volume of 0.02 million shares and above its 52-week average volume of 0.16 million shares. Over the last five days, Agrieuro Corp.'s shares have advanced 5.13% and over the last three months, the stock has gained 556.00%. However, in the past one month, the stock has lost 18.00%. On a compounded annual basis, the company has returned 958.06% in the last three months. Further, the company is trading at a price to book ratio of 12.6. Besides, the market cap of the company stood at USD 105.0 million.
- Cannabis Science Inc.'s stock increased by 17.95% to close trading at USD 0.02, below its 50-day and 200-day moving average of USD 0.03 each. During the session, a total of 9.06 million shares exchanged hands, which surpassed its 50-day daily average volume of 4.78 million shares and was above its 52-week average volume of 5.18 million shares. Over the last three days, Cannabis Science Inc.'s shares have advanced 10.05%. Furthermore, over the last three months, the stock has gained 35.29% while shedding 33.33% in the past six months. On a compounded total return basis, the company has returned 30.68% in the past three months. Additionally, the stock is trading at a price to sales ratio of 183.81. Further, the company has a market cap of USD 29.5 million. Cannabis Science, engaged in medical marijuana research and development, works on phytocannabinoid science focusing critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.
- Hyperdynamics Corporation's stock added 11.56% to close Friday's session at USD 1.64, above its 50-day and 200-day moving average of USD 0.87 and USD 0.72, respectively. The company's shares oscillated between USD 1.47 and USD 1.67. The stock recorded a trading volume of 0.18 million shares, which was above its 50-day daily average volume of 0.03 million shares and above its 52-week average volume of 0.06 million shares. Over the last five days, Hyperdynamics Corporation's shares have advanced 42.61% and in the past one month, it has gained a momentum of 105.00%. In addition, over the last three months, the stock has gained 164.52% and year to date, the shares have picked up 112.99%. On a compounded total return basis, the company has returned 1.23% in the past one year. Additionally, Hyperdynamics Corporation is trading at a price to book ratio of 1.1 and has a market cap of USD 34.5 million.
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
RESTRICTIONS
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice
